drugset / Trial / NCT01158300
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Phase 1
Completed
28 enrolled
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI) · collabPTC Therapeutics · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: PTC299 may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and the best dose of PTC299 in treating young patients with recurrent or refractory primary central nervous system tumors.
Timeline
- Start
- 2010-11
- Primary completion
- 2015-01
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EMVODODSTAT | Small molecule | 0.6 mg/kg | Oral |
| Subject | EMVODODSTAT | Small molecule | 1.2 mg/kg | Oral |
| Subject | EMVODODSTAT | Small molecule | 1.5 mg/kg | Oral |
| Subject | EMVODODSTAT | Small molecule | 2 mg/kg | Oral |